GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2007

Immtech’s Pneumocystis Pneumonia Drug Licensed by Par in $147M Deal

  • Immtech Pharmaceuticals granted Par Pharmaceutical an exclusive license to commercialize its treatment of pneumocystis pneumonia (PCP) in AIDS patients in the U.S. Pafuramidine maleate is the company’s lead oral drug. 

    The companies may also collaborate on efforts to develop pafuramidine as a preventative therapy for patients at risk of developing PCP, including people living with HIV, cancer, and other immunosuppressive conditions.

    According to the terms of the signed agreement, Immtech received an initial payment of $3 million from Par. An additional $29 million will be paid as pafuramidine advances through ongoing Phase III trials and U.S. regulatory review and approval. Immtech also will receive royalties as well as up to $115 million in sales-based milestones. Immtech retains the right to co-market pafuramidine in the U.S.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?